UPDATE: Diagnostyka announces plans for IPO and listing of its shares on Warsaw Stock Exchange
Diagnostyka, the leading provider of diagnostics services in Poland operating in the market for almost 27 years, announces its intention to conduct an initial public offering IPO of its shares. Diagnostyka intends to apply for admission and listing of the company's shares on the regulated market of the Warsaw Stock Exchange.
As stated, the planned offering will involve the sale of existing shares held by the company's shareholder LX Beta S.à r.l., controlled by the MidEuropa III Management Limited, which currently holds 47.83 percent of the company's shares. The remaining shares are held by the company's founders, key management and board members, who will not sell shares in the offering.
No new shares in the company's share capital will be issued or offered in connection with the offering.
The offering will be addressed to retail and institutional investors in Poland and selected international institutional investors in certain other jurisdictions and qualified institutional buyers in the United States.
The Diagnostyka Group is a leading provider of diagnostic services with the largest network of medical laboratories and blood collection points in Poland. The Group started operating in the market in 1998, since then it has built a leading market position in terms of the number of laboratories and blood collection points operated, the total number of tests performed, the number of specialists employed and the size of its own courier network.
nl/
